FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.
What happened
FDA inspected Drug Depot, LLC dba APS Pharmacy in Palm Harbor, Florida, from June 6 to June 17, 2022. Investigators found the firm compounded drug products using bulk drug substances that failed section 503A conditions: the substances lacked applicable USP/NF monographs or approved-drug status and were not on the 503A bulks list, and some were made by establishments not registered under section 510 of the FDCA. FDA also said the firm's responses to the Form FDA 483 (inspection findings) did not address these issues.
What FDA found
The firm compounded drugs with bulk drug substances that are not the subject of a USP or NF monograph, are not components of FDA-approved drugs, and are not on the 503A bulks list.
FDCA section 503A(b)(1)(A)(i) [21 U.S.C. § 353a]The firm used bulk drug substances made by establishments not registered under section 510 of the FDCA.
FDCA section 503A(b)(1)(A)(ii) [21 U.S.C. § 360]Because the compounded products did not qualify for section 503A exemptions, they were unapproved new drugs without FDA-approved applications.
FDCA sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]The products' labeling lacked adequate directions for use for conditions not suitable for self-diagnosis and treatment, making them misbranded.
FDCA section 502(f)(1) [21 U.S.C. § 352(f)(1)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, including supporting documents. If it cannot fully address the matter in that time, it must explain the delay and give a completion date.
Who should pay attention
- compounding pharmacies that use bulk drug substances
- healthcare providers who purchase compounded drugs
- bulk ingredient suppliers verifying registration status
This is a summary. Read the original letter on fda.gov.